Peptide Research Database

Access 7,487 peer-reviewed studies, clinical trials, and research papers on peptides. Filter by key research, study type, compound, and category. Direct links to full PubMed entries for comprehensive, evidence-based exploration.

Review
Notable
PMID: 42993255
2026 Nov 06

Clinical pharmacology of antidiabetic drugs: an update.

In a research review, overall, a comprehensive understanding of the pharmacologic characteristics of antidiabetic drugs promotes appropriate drug use for the management of T2D and cardiometabolic diseases and helps avoid undesirable events.

Wichaiyo S

This review describes the updated pharmacology of antidiabetic drugs and its translation into clinical applications. English language literature published from January 1, 1998 to July 25, 2026 was collected using PubMed, ScienceDirect, and Ovid. Research articles, reviews, and clinical practice guidelines were included for discussion. Currently, ultra-long-acting basal insulins are emerging, allowing less frequent injections. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), tirzepatide, and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have novel pharmacodynamic properties and clinical evidence of cardiorenal and metabolic benefits, supporting their important roles in individuals with type 2 diabetes (T2D) who have high cardiorenal risk. Because of their effects on weight reduction, GLP-1RAs (semaglutide, liraglutide, and orforglipron) and tirzepatide are approved for the treatment of obesity. Furthermore, SGLT2is (empagliflozin, dapagliflozin, and sotagliflozin) provide cardiorenal benefits, with supporting potential mechanisms, in individuals with heart failure and chronic kidney disease. Conventional oral drugs (e.g., metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, and α-glucosidase inhibitors) lack sufficient pharmacologic and clinical data on cardiorenal benefits, suggesting their roles as adjunctive therapies. Novel candidates, including triple incretin hormone agonists (acting on GLP-1, glucose-dependent insulinotropic polypeptide [GIP], and glucagon receptors), GLP-1RA-GIP antagonism-based therapies, amylin analogues, and new dual SGLT1/2 inhibitors, show promising results for glycemic control and weight loss. Overall, a comprehensive understanding of the pharmacologic characteristics of antidiabetic drugs promotes appropriate drug use for the management of T2D and cardiometabolic diseases and helps avoid undesirable events. Ongoing investigations of novel approaches may contribute to improved patient care in the future.

European journal of clinical pharmacology
Animal Study
Notable
PMID: 42989960
2026 Nov 06

A Nature-Derived Peptide Promotes Satiety Hormone Response and Weight Loss In Vivo.

In a mouse study, NDP-35 and NDP-45 are promising preclinical food-protein-derived peptide candidates that stimulate enteroendocrine hormone responses and reduce food intake and body weight in rodent models, warranting further evaluation as an oral approach to appetite and body-weight control.

Abramov M, Goldfarb E, Haham D, Akiva E, van Klinken JW, Barbash Z

The global rise of obesity highlights the critical need for effective weight-management strategies. GLP-1 receptor agonists have transformed obesity care, yet gastrointestinal intolerance, high cost, and weight regain after discontinuation highlight the need for complementary, orally available options. An alternative is to stimulate the body's own GLP-1 release through the nutrient-sensing GPCRs on enteroendocrine L cells that a meal engages. Using an AI-guided screen of common food proteins, we identified nature-derived peptides (NDPs): sequences native to edible proteins that were reproduced synthetically and engage these receptors. Unlike peptide drugs engineered for systemic exposure, NDPs are intended to act locally at the gut epithelium. Our lead, NDP-35 (from Coffea arabica), is a potent, selective GPR40 agonist (EC50 = 32.7 nM); in mice, it raised plasma GLP-1, GIP, and PYY while lowering hunger hormones, reproducing the coordinated satiety hormone response of a meal at minimal caloric cost. Over 28 days of oral dosing in diet-induced obese rats, NDP-35 reduced food intake and lowered body weight by ∼5%, versus a 3% gain in vehicle-treated animals; a subcutaneous semaglutide arm was included as a reference comparator and endpoint values were of similar magnitude to NDP-35. Terminal clinical chemistry and organ-weight markers showed no treatment-related changes over the dosing period. A structurally distinct peptide, NDP-45 (from banana), reproduced these effects. NDP-35 and NDP-45 are promising preclinical food-protein-derived peptide candidates that stimulate enteroendocrine hormone responses and reduce food intake and body weight in rodent models, warranting further evaluation as an oral approach to appetite and body-weight control.

Journal of dietary supplements
Other
PMID: 42998617
2026 Nov 06

A UHPLC-MS/MS method for the quantification of oxytocin in human saliva.

This study found overall, the method was able to accurately quantify oxytocin levels in real-world samples, thus demonstrating its applicability in epidemiological studies. Aimed to develop and validate a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of oxytocin in human saliva, in accordance with EMA and FDA guidelines for bioanalytical method validation.

Soloperto S, Mula J, Chiara F, Favata F, Menegatti G, Genova EC, Maiese D, Palermiti A, De Nicolò A, Simiele M, Pezzati R, D'Avolio A, Cantù M

Given the reported correlation between cerebrospinal fluid (CSF) and salivary oxytocin concentrations, salivary oxytocin has been proposed as a promising peripheral biomarker of central oxytocin activity. To date, oxytocin levels are commonly measured using enzyme immunoassays or radio-immunoassays; however, several challenges related to its accurate quantification have been reported, underscoring the need for a standardized and reliable analytical method. The present study aimed to develop and validate a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of oxytocin in human saliva, in accordance with EMA and FDA guidelines for bioanalytical method validation. Oxytocin levels were determined using the standard addition method. The chromatographic separation was performed through a gradient elution of two mobile phases (H2O + 0.1% F.A. and MeOH: DMSO 97:3 (v/v) + 0.1% F.A.) using a Phenomenex Luna Omega 1.6 μm PS C18 100 Å LC Column 50 × 2.1 mm at 40°C with a column thermostat. It was connected to a tandem mass spectrometer, and the chromatographic run lasted 5 min. Additionally, in order to evaluate precision and accuracy of the method, real-world samples from caregivers working with people with dementia were analyzed. Method validation achieved satisfactory results in terms of robustness and reproducibility, especially at higher concentration values, while expected higher variability at lower concentrations was observed. However, real-world samples analysis confirmed the applicability of the method to real biological samples. Overall, the method was able to accurately quantify oxytocin levels in real-world samples, thus demonstrating its applicability in epidemiological studies.

Psychoneuroendocrinology
Other
PMID: 42993840
2026 Nov 06

The (amide-)N-methylnicotinamide is a microbe-derived NAD+ precursor that drives gut stem cell renewal.

In a mouse study, compared to known NAD precursors, N-MNA brings a methyl group into host cells, representing a class of microbe-derived NAD precursor that stimulates the tissue regenerative power.

Han J, Antonio JM, Bhupana JN, Choi G, Yang J, Chiles E, Tong Y, Rajmohamed MA, Wu HT, Wang D, Meadows V, Lapaque N, Etchegaray JP, Filip R, Liu TC, Kiela PR, Bessman N, Ferraris RP, Wong CO, Su X, Gao N

Nicotinamide Adenine Dinucleotide (NAD) is a critical cellular coenzyme whose decline associates with various chronic and inflammatory diseases. Improved NAD restoration may reduce disease risks and extend healthy lifespan. We report here that certain commensal bacteria including specific probiotic species produce (amide-)N-methylnicotinamide (N-MNA), which is a structural isomer of methylnicotinamide, a nicotinamide degradative metabolite. Patients with gut dysbiosis and inflammation show reduced stool N-MNA. Stable isotope tracing revealed that N-MNA can be rapidly taken up and incorporated into NAD redox reactions by intestinal epithelial cells (IECs) and non-IECs of fruit fly, mouse, and human. Genetic and pharmacological analyses suggest that N-MNA is converted to NAD+ via the Preiss-Handler pathway, independent of the salvage pathway. Cell-type-specific ablation or overexpression of SIRT1, an NAD-consuming enzyme, in Drosophila, along with intestinal stem cell (ISC) lineage tracing in mice revealed that systemic N-MNA supplementation promotes ISC regeneration and gut epithelial repair. Compared to known NAD precursors, N-MNA brings a methyl group into host cells, representing a class of microbe-derived NAD precursor that stimulates the tissue regenerative power.

Science advances
Meta-Analysis
Landmark Study
PMID: 42994759
2026 Nov 06

Exploring time-varying cardiovascular effects of GLP-1 receptor agonists: A multi-state network meta-analysis of cardiovascular outcome trials.

In a combined analysis of multiple studies, these data did not establish a reliable efficacy hierarchy or empirically distinguish event prevention from post-event survival effects.

Wang Z, Zhang P, Zhang Y, Bai J

To explore time-varying cardiovascular effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and transition-specific estimates obtainable from published outcome curves. Ten placebo-controlled cardiovascular outcome trials included 87,334 participants and eight GLP-1 RA regimens. Reconstructed major adverse cardiovascular event (MACE) data and all-cause mortality data, directly reconstructed for four trials and synthesised for four, informed a three-state model. Two trials contributed MACE data only. The model assumed no treatment effect on death before a first non-fatal MACE. Conventional random-effects meta-analysis provided a comparator. Conventional meta-analysis yielded a MACE hazard ratio (HR) of 0.856 (95% confidence interval 0.810-0.905). Modelled transition HRs for first non-fatal MACE at 24 months ranged from 0.51 to 1.38; all 95% credible intervals included 1. Semaglutide posterior median curves suggested larger early reductions that attenuated over time. Mortality attribution depended on structural assumptions, and several sensitivity analyses showed incomplete convergence. Conventional synthesis supported a class-level MACE reduction. Multi-state estimates suggested possible time-varying patterns but remained imprecise and assumption-dependent. These data did not establish a reliable efficacy hierarchy or empirically distinguish event prevention from post-event survival effects.

Diabetes research and clinical practice
Other
PMID: 42993217
2026 Nov 06

Disproportionality analysis of ventricular extrasystoles reported with semaglutide in VigiBase and the FDA Adverse Event Monitoring System.

This study found although spontaneous reporting data cannot establish incidence, causality, or prognostic significance, this finding warrants prospective investigation using systematic electrocardiographic assessment and ambulatory rhythm monitoring.

Wu D, Yang R, Zeng J, Bai Z, Zhang C, Fan X, Zhou X, Wu L, Zhu S, Akin I, Zhou X, Chang L, Hashimoto K, Wei Y

Semaglutide is widely used to treat type 2 diabetes and obesity and to reduce cardiovascular risk. However, its association with cardiac rhythm-related adverse-event reporting in routine clinical practice remains incompletely characterized. To investigate cardiovascular and rhythm-related adverse-event reporting associated with semaglutide, with a focus on ventricular extrasystoles, we conducted a disproportionality analysis of individual case safety reports from VigiBase and the FDA Adverse Event Monitoring System (AEMS; formerly the FDA Adverse Event Reporting System [FAERS]). Reports were included when semaglutide was recorded as a suspected drug, according to database-specific criteria. Cardiovascular outcomes were identified using Medical Dictionary for Regulatory Activities Preferred Terms. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) were calculated. A cross-database reporting signal was defined as at least three semaglutide-associated reports and a lower 95% CI bound exceeding 1 in each database. After deduplication and application of the predefined inclusion criteria, 1980 semaglutide-associated cardiovascular reports from VigiBase and 1754 from AEMS were included. Among the screened cardiovascular and rhythm-related preferred terms, ventricular extrasystoles was the only term that met the prespecified signal criterion in both databases. Ventricular extrasystoles, clinically corresponding to premature ventricular contractions, showed disproportionate reporting in VigiBase (ROR 1.77, 95% CI 1.31-2.40) and AEMS (ROR 1.37, 95% CI 1.00-1.88; unrounded lower CI bound > 1). Ventricular extrasystoles showed a consistent disproportionality signal across VigiBase and AEMS. Although spontaneous reporting data cannot establish incidence, causality, or prognostic significance, this finding warrants prospective investigation using systematic electrocardiographic assessment and ambulatory rhythm monitoring.

Naunyn-Schmiedeberg's archives of pharmacology
Animal Study
Notable
PMID: 42994705
2026 Nov 06

Mitochondrial-derived peptide humanin alleviates AKI-to-CKD transition by inhibiting TRIM28-mediated ubiquitination of Suclg1.

In a mouse study, humanin, a protein fragment derived from mitochondria, prevented kidney fibrosis after acute kidney injury through a specific molecular mechanism. The protective effect depended on stabilizing a key enzyme involved in energy production, suggesting humanin as a potential treatment target.

Lu X, Chen Q, Gao Y, Tao S, Qiu J, Huang L, Jiang G, Zhang N, Chen M, Guo Y, Zhang L

Acute kidney injury (AKI) resulting from ischemia-reperfusion injury (IRI) may subsequently progress to chronic kidney disease (CKD) and eventually end-stage renal disease (ESRD). Humanin, a mitochondria-derived peptide, has been implicated in various physiological and pathological processes and exhibits cytoprotective effects against inflammation, apoptosis, and oxidative stress. Nevertheless, its role in the AKI-to-CKD transition remains poorly understood. This study showed that renal humanin expression was downregulated in a murine IRI model and this reduction was significantly correlated with renal function decline and kidney fibrosis progression. Exogenous supplementation of S14G-humanin (HN) was found to protect against kidney fibrosis induced by IRI. Mechanistically, HN attenuated kidney fibrosis by stabilizing succinate-CoA ligase subunit alpha (Suclg1) by inhibiting tripartite motif-containing protein 28 (TRIM28)-mediated ubiquitination of Suclg1. Inhibition of Suclg1 abolished the renoprotective effects of HN, underscoring the critical role of Suclg1 in the AKI-to-CKD transition. Moreover, HN-mediated upregulation of Suclg1 reduced superoxide dismutase 2 (SOD2) succinylation, linking metabolic reprogramming to mitochondrial dysfunction and fibrotic progression. Collectively, these findings reveal a critical role of humanin in mitigating kidney fibrosis and identify Suclg1 as a promising therapeutic target in the AKI-to-CKD transition.

Free radical biology & medicine
Animal Study
Notable
PMID: 42993361
2026 Nov 06

DJ1 attenuates iron accumulation and ferroptosis-associated lung injury in association with SAHH activity and glutathione homeostasis.

In a mouse study, these findings support a role for DJ1 in limiting iron accumulation and ferroptosis-associated lung injury and are consistent with a contribution of SAHH activity.

Tang J, Dong W, Wang D, Deng Q, Li Y, Xiao G

Iron-dependent ferroptosis has emerged as an important pathological mechanism in acute lung injury, but the endogenous mechanisms that limit iron accumulation and lipid peroxidation during lung injury remain incompletely understood. We investigated whether DJ1 (Parkinson disease protein 7, encoded by PARK7), a cytoprotective protein induced by oxidative stress, limits iron accumulation and ferroptosis in lipopolysaccharide (LPS)-induced acute lung injury. Experiments were performed in male C57BL/6J mice challenged with intratracheal LPS and in Beas-2B human bronchial epithelial cells treated with the ferroptosis inducer erastin. LPS challenge in mice and erastin treatment in cells increased total iron content and produced changes consistent with ferroptosis, including glutathione depletion, malondialdehyde accumulation, and reduced expression of glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11). C11-BODIPY analysis directly confirmed erastin-induced lipid peroxidation, and among the regulated cell death inhibitors tested, only ferrostatin-1 (Fer-1) substantially restored cell viability. DJ1 expression rose under both conditions. Adeno-associated virus-mediated DJ1 overexpression, delivered three weeks before LPS challenge, attenuated iron accumulation and lung injury, whereas DJ1 knockdown worsened both. Co-immunoprecipitation showed that DJ1 was associated with S-adenosylhomocysteine hydrolase (SAHH), an enzyme linked to methionine metabolism and glutathione synthesis. Higher DJ1 levels were accompanied by lower AHCYL1-SAHH association and higher SAHH activity. After treatment with adenosine periodate-oxidized (AdOx), the protection associated with DJ1 overexpression was no longer observed. Fer-1 produced protection similar to that associated with DJ1 overexpression. These findings support a role for DJ1 in limiting iron accumulation and ferroptosis-associated lung injury and are consistent with a contribution of SAHH activity. The precise contribution of the DJ1-SAHH-AHCYL1 relationship requires further mechanistic validation.

Journal of molecular histology
Other
PMID: 42995259
2026 Nov 06

NAD+ precursor fails in Parkinson's disease.

Attwaters M

Nature aging
Other
PMID: 42994978
2026 Nov 06

Semaglutide (Wegovy) for secondary cardiovascular prevention in adults with an elevated BMI.

Drug and therapeutics bulletin